The current poor understanding of the pharmacologicaland pathologicalimpact of xylazine on humans hampers the ability to treat patientswith complicated use-dependence syndromes.59 Our study reveals that xylazine is a strong competitive inhibitorof α7 nAChRs. This evidence concerns the gene CHRNA7 and nicotine dependence.